Table 3.
Immunological results in Covid-19 convalescent CLL patients.
| Patient number | Serologya | Neutralizing antibodies | Antibodies in Salivac | ELISpot assay (IFN-gamma)d | |||||
|---|---|---|---|---|---|---|---|---|---|
| 3 mob Pos/Neg | 6 mob Pos/Neg | 12 mob Pos/Neg | Pos/Negb | Pos/Negb Anti-Spike MFI | Spike specific T cells/CD3+ (%) | Spike specific SFUs | Spike specific T cells/uL | Pos/Negb | |
| 003 | Pos | Pos | Pos | ++ (7) | Pos (13) | 0.09 | 44 | 1 | Pos (7) |
| 007 | – | Pos | Pos | ++ (7) | Pos (13) | 0.2 | 46 | 3 | Pos (7) |
| 015 | – | Pos | – | +++ (5) | Pos (11) | 1.4 | 1032 | 59 | Pos (5) |
| 012 | Pos | Pos | Pos | + (5) | Neg (10) | 0.35 | 380 | 1.5 | Pos (5) |
| 011 | Pos | Pos | Pos | +++ (6) | Pos (12) | 0.15 | 32 | 2 | Pos (6) |
| 024 | – | Pos | Pos | + (8) | Neg (13) | 0.1 | 26 | 1.5 | Pos (8) |
| 014 | Pos | Pos | – | +++ (6) | – | 0.7 | 292 | 16 | Pos (6) |
| 017 | Pos | Pos | – | +++ (4) | – | 0.6 | 562 | 3.5 | Pos (4) |
| 030 | Pos | Pos | Pos | +++ (7) | – | 0.1 | 42 | 3.5 | Pos (7) |
| 020 | Pos | Neg | Neg | Neg (8) | – | 0.5 | 456 | 4.5 | Pos (8) |
| 010 | Neg | Neg | Neg | Neg (6) | Pos (12) | 2.2 | 2712 | 9.5 | Pos (6) |
| 013 | – | Pos | – | ++ (5) | Pos (10) | 0.2 | 26 | 2.5 | Pos (5) |
| 023 | Pos | Pos | – | + (3) | Pos (6) | 0.02 | 4 | 0.6 | Neg (3) |
| 009 | Neg | Neg | Neg | Neg (7) | Neg (11) | 0.04 | 18 | 0.3 | Neg (7) |
| 004 | – | Neg | Pose | Neg (9) | Pos (13) | 0 | 0 | 0 | Neg (9) |
| 052 | Pos | Pos | – | – | Pos (4) | – | – | – | – |
| 058 | Pos | – | – | – | Pos (3) | – | – | – | – |
| 060 | Pos | Pos | – | – | Pos (4) | – | – | – | – |
| 043 | Pos | Pos | – | – | Pos (6) | – | – | – | – |
| 019 | – | Pos | Pos | +++ (7) | Pos (12) | 0 | 0 | 0 | Posf (7) |
| 026 | Pos | – | – | – | Neg (5) | – | – | – | – |
| 035 | Pos | – | – | – | Pos (4) | – | – | – | – |
| 027 | Pos | – | – | – | Neg (5) | – | – | – | – |
| 047 | Pos | – | – | – | Pos (4) | – | – | – | – |
| 059 | Pos | – | – | – | Neg (2) | – | – | – | – |
| 037 | – | Pos | – | – | Pos (6) | – | – | – | – |
| 032 | Neg | – | – | – | Neg (4) | – | – | – | – |
| 025 | Neg | – | – | + (3) | Neg (6) | 0.15 | 32 | 4 | Pos (3) |
| 018 | Neg | Neg | – | – | – | – | – | – | – |
| 036 | Pos | – | – | – | – | – | – | – | – |
| 038 | Pos | – | – | – | – | – | – | – | – |
| 044 | Pos | – | – | – | – | – | – | – | – |
| 046 | Pos | Pos | – | – | – | – | – | – | – |
| 051 | Neg | – | – | – | – | – | – | – | – |
| 055 | Pos | – | – | – | – | – | – | – | – |
| 057 | Pos | – | – | – | – | – | – | – | – |
| 061 | Pos | – | – | – | – | – | – | – | – |
| 062 | Pos | – | – | – | Pos (3) | – | – | – | – |
| 034 | Pos | – | – | – | Pos (3) | – | – | – | – |
| 029 | Neg | – | – | – | – | – | – | – | – |
| 040 | – | – | – | – | Pos (6) | – | – | – | – |
| 048 | Pos | – | – | – | Neg (4) | – | – | – | – |
– no data available.
anucleocapsid and/or spike – see Methods.
bnumber indicate time (months) from Covid-19 diagnosis to test.
csaliva antibody reactivity against the Spike S1S2 trimer. For MFI (median fluorescence intensity) value, see supplementary Table S3.
dELISpot was considered positive if >20 SFUs in Spike-based and/or M + N + E –based tests.
enegative at 6 months against Nucleocapside, positive at 12 months against Spike.
fpositive due to 40 spots in the M + N + E analysis.